Meld and Peld: Application of survival models to liver allocation

Liver Transplantation

Volumn 7, Issue 7, 2001, Pages 567-580

  Wiesner, Russell H ^a   McDiarmid, Sue V ^a   Kamath, Patrick S ^a   Edwards, Eric B ^a   Malinchoc, Michael ^a   Kremers, Walter K ^a   Krom, Ruud A F ^a   Kim, W Ray ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; HEALTH CARE POLICY; HOSPITAL ADMISSION; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MORTALITY; OUTCOMES RESEARCH; PEDIATRICS; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; SCORING SYSTEM; STATISTICAL MODEL; SURVIVAL; TIME; VALIDATION PROCESS;

EID: 0034920207     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.25879     Document Type: Article

References (64)

1. Organ procurement and transplantation network-HRSA. Final rule with comment period
2. Analysis of waiting times
3. Liver transplant waiting time does not correlate with waiting list mortality: Implications for liver allocation policy
4. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases
5. Surgery and portal hypertension
6. A peek at the Child-Turcotte classification
7. Transection of the oesophagus for bleeding oesophageal varices
8. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis
9. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics
10. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis
11. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis
12. Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of the Child-Pugh score in nonbleeding advanced cirrhotics
13. A prognostic model for predicting survival in cirrhosis with ascites
14. Diagnosis of functional renal failure of cirrhosis by Doppler sonography. Prognostic value of resistive index
15. Prognosis of cirrhosis with ascites
16. Prothrombin time in liver failure: Time, ratio, activity percentage, or international normalized ratio?
17. Prognosis in primary biliary cirrhosis: Model for decision making
18. Natural history and prognostic variables in primary sclerosing cholangitis
19. Primary sclerosing cholangitis: Natural history, prognostic factors, and survival analysis
20. Assessment of prognostic factors in alcoholic liver disease: Toward a global quantitative expression of severity
21. Prognostic factors in alcoholic liver disease
22. Wilson's disease: Clinical presentation and use of prognostic index
23. Alcoholic liver disease: Evaluation of natural history and prognostic factors
24. Corticosteroid therapy of alcoholic hepatitis
25. Updating prognosis and therapeutic effect evaluation in cirrhosis with Cox's multiple regression model for time-dependent variables
26. Survival and prognostic indicators in compensated and decompensated cirrhosis
27. Compensated cirrhosis: Natural history and prognostic factors
28. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis
29. Aminopyrine breath test in prognostic evaluation of patients with cirrhosis
30. 14C-aminopyrine breath test compared to the Child-Pugh score and serum bile acids in 84 cirrhotic patients
31. Monoethylglycinexylidide test: A prognostic indicator of survival in cirrhosis
32. Predictors of one year pretransplant survival in patients with cirrhosis
33. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation
34. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis
35. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites
36. A prognostic model for patients with end-stage liver disease
37. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts
38. A model to predict survival in patients with end-stage liver disease
39. The meaning and use of the area under a receiver operating characteristic (ROC) curve
40. Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and Child-Pugh score
41. Which patients with cirrhosis should undergo endoscopic screening for esophageal variceal detection?
42. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis
43. Prognostic significance of hepatic encephalopathy in patients with cirrhosis
44. The course of patients after variceal hemorrhage
45. Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation
46. Sclerotherapy of esophageal varices: Long-term results and determinants of survival
47. Influence of hepatic reserve and cause of esophageal varices on survival and rebleeding before and after the introduction of sclerotherapy: A retrospective analysis
48. The Emory prospective randomized trial: Selective versus nonselective shunt to control variceal bleeding: Ten year follow-up
49. Liver transplantation for alcoholic liver disease: A survey of transplantation in the United States
50. Optimal timing of liver transplantation for primary biliary cirrhosis
51. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis
52. Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
53. Ursodiol for primary sclerosing cholangitis
54. Mayo end-stage liver disease model (MELD) score predicts liver transplant waiting list mortality: Implications for liver allocation policy
55. Preliminary results of a liver allocation plan using a continuous medical severity score that de-emphasizes waiting time
56. Development of a pediatric end-stage liver disease score
57. Serum creatinine and fat-free mass (lean body mass)
58. Prediction of creatinine clearance from creatinine
59. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma
60. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis
61. Prediction of liver transplant outcome using the MELD scale